
Reset all filters
01 4Evrenzo
02 4Roxadustat
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 21
2020 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 174
2020 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 24
2021 Revenue in Millions : 22
Growth (%) : 11
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 197
2021 Revenue in Millions : 174
Growth (%) : 13
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 5
2022 Revenue in Millions : 24
Growth (%) : -75
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 271
2022 Revenue in Millions : 197
Growth (%) : 38
Main Therapeutic Indication : Hematology
Currency : USD
2024 Revenue in Millions : 0
2023 Revenue in Millions : 8
Growth (%) : -100
Main Therapeutic Indication : Hematology
Currency : USD
2024 Revenue in Millions : 331
2023 Revenue in Millions : 271
Growth (%) : 22